Want to track IVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035.
Seekingalpha | 2 years ago
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks | 2 years ago
